Sandoz Group (OTCMKTS:SDZNY) Cut to Hold at Royal Bank Of Canada

Royal Bank Of Canada downgraded shares of Sandoz Group (OTCMKTS:SDZNY) from a moderate buy rating to a hold rating in a research note released on Monday,Zacks.com reports.

SDZNY has been the subject of several other reports. Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. Barclays downgraded Sandoz Group from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Sandoz Group Stock Performance

Sandoz Group stock opened at $77.53 on Monday. The firm has a fifty day moving average of $81.53 and a 200-day moving average of $71.96. Sandoz Group has a 52-week low of $35.61 and a 52-week high of $94.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.29 and a quick ratio of 0.82.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.